Psychosis Associated With Alzheimer's Disease Clinical Trials

10 clinical trials for Psychosis Associated With Alzheimer's Disease across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — RECRUITING · PHASE2
• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease — RECRUITING · PHASE2
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) — RECRUITING · PHASE3
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis — RECRUITING · PHASE2
• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) — RECRUITING · PHASE3
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) — RECRUITING · PHASE3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-4) — TERMINATED · PHASE3
• A Multicenter, Randomized, Double-blind, Placebo-controlled, Flexible-dose Study to Assess the Efficacy, Safety, and Tolerability of ITI1284 in Patients with Psychosis Associated with Alzheimer’s Disease — TERMINATED · PHASE2
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimer’s Disease (ADEPT-3) — TERMINATED · PHASE3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimer’s Disease (ADEPT-2) — TERMINATED · PHASE3

Refine this search